Investigational Studies

NEW YORK, September 12, 2017 /PRNewswire/ — With leading recent estimates clocking the 2016 North American legal cannabis market between $6.7 and $7.2 billion, the only thing more impressive about the industry is the growth projections. Research estimates a whopping compound annual sales growth rate of 25 percent through 2021. This stupendous growth, driven by […]

by

– Morgan Stanley 15th Annual Global Healthcare Conference on 13 September –            – Leerink Partners Rare Disease Immuno-Oncology Roundtable Series on 27 September – LONDON, Sept. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today […]

by

– Morgan Stanley 15th Annual Global Healthcare Conference on 13 September – – Leerink Partners Rare Disease Immuno-Oncology Roundtable Series on 27 September –   London, UK, 5 Sept 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced […]

by

– Morgan Stanley 15th Annual Global Healthcare Conference on 13 September –            – Leerink Partners Rare Disease Immuno-Oncology Roundtable Series on 27 September – LONDON, Sept. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today […]

by

Biopharmaceutical company, GW Pharmaceuticals announced that the European Medicines Agency (EMA) has granted orphan drug designation to GW’s investigational product Epidiolex (cannabidiol [CBD]) in the treatment of Lennox-Gastaut Syndrome (LGS), a treatment-resistant, debilitating childhood-onset epilepsy. “Following two positive Phase III trials of Epidiolex in patients with LGS, GW is committed to pursuing registration of Epidiolex in Europe […]

by

– Epidiolex® NDA submission process underway – – Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results […]

by

brainPhoto Credit: Berkeley Lab In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical […]

by

In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical company focused on […]

by

In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical company focused on […]

by